Purpose of Study: This research is being done to understand why autoimmune disease develops after certain cancer treatments and how to best monitor and manage patients with this issue. We also want to study participants with pre-existing autoimmune disease to understand how to safely use immunotherapy for cancer treatment in this group of people.
- Age > 18
- Patients on immune checkpoint inhibitors to treat cancer with new or existing autoimmune or inflammatory symptoms
Michelle K. Jones, B.S.
Assistant Professor of Medicine
Dr. Laura C. Cappelli is an Assistant Professor of Medicine at the Johns Hopkins University School of Medicine, Division of Rheumatology, and a faculty member of the Johns Hopkins Arthritis Center. She earned her M.D. from Johns Hopkins. She completed her residency in internal medicine and fellowship in rheumatology at the Johns Hopkins Hospital. Dr. Cappelli also received her MHS in Clinical Investigation from the Johns Hopkins Bloomberg School of Public Health. Her primary research focus is rheumatologic adverse effects of cancer immunotherapy including the clinical characteristics, epidemiology, impact on patients, and biologic mechanisms of these adverse events. She also performs clinical and translational research in rheumatoid arthritis.